Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Norhammar

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
The Lancet. Diabetes & Endocrinology|August 8, 2017
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisKåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, et al.
Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.
Circulation|January 15, 2016
Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK StudyLars Rydén, Kåre Buhlin, Eva Ekstrand, et al.
Diabetes, Obesity & Metabolism|November 28, 2025
SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complicationsJan W Eriksson, Giovanni Fanni, Martin H Lundqvist, et al.
Heart (British Cardiac Society)|February 13, 2023
Prevalence, outcomes and costs of a contemporary, multinational population with heart failureAnna Norhammar, Johan Bodegard, Marc Vanderheyden, et al.
Journal of Clinical Periodontology|September 12, 2024
Does Periodontitis Increase the Risk for Future Cardiovascular Events? Long-Term Follow-Up of the PAROKRANK StudyAnna Norhammar, Per Näsman, Kåre Buhlin, et al.
Diabetes, Obesity & Metabolism|March 24, 2018
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL studyMikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational studyFrederik Persson, Johan Bodegard, Jorma T Lahtela, et al.
Journal of the American College of Cardiology|June 2, 2018
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALMatthew A Cavender, Anna Norhammar, Kåre I Birkeland, et al.
Circulation|May 20, 2017
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
The Lancet. Diabetes & Endocrinology|August 8, 2017
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisKåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, et al.
Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.
Circulation|January 15, 2016
Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK StudyLars Rydén, Kåre Buhlin, Eva Ekstrand, et al.
Diabetes, Obesity & Metabolism|November 28, 2025
SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complicationsJan W Eriksson, Giovanni Fanni, Martin H Lundqvist, et al.
Heart (British Cardiac Society)|February 13, 2023
Prevalence, outcomes and costs of a contemporary, multinational population with heart failureAnna Norhammar, Johan Bodegard, Marc Vanderheyden, et al.
Journal of Clinical Periodontology|September 12, 2024
Does Periodontitis Increase the Risk for Future Cardiovascular Events? Long-Term Follow-Up of the PAROKRANK StudyAnna Norhammar, Per Näsman, Kåre Buhlin, et al.
Diabetes, Obesity & Metabolism|March 24, 2018
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL studyMikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational studyFrederik Persson, Johan Bodegard, Jorma T Lahtela, et al.
Journal of the American College of Cardiology|June 2, 2018
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALMatthew A Cavender, Anna Norhammar, Kåre I Birkeland, et al.
Circulation|May 20, 2017
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, et al.
Pageof 11